172 related articles for article (PubMed ID: 3825224)
1. [QT time and the ventricular refractory period in programmed electrical stimulation of the heart in patients with ventricular and supraventricular tachycardias--effect of sotalol].
Wehr M
Z Kardiol; 1986 Dec; 75(12):744-50. PubMed ID: 3825224
[TBL] [Abstract][Full Text] [Related]
2. [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias].
Trappe HJ; Klein H; Lichtlen PR
Z Kardiol; 1987 Oct; 76(10):630-4. PubMed ID: 3687165
[TBL] [Abstract][Full Text] [Related]
3. [Sotalol in supraventricular tachycardia. Electrophysiologic measurements in Wolff-Parkinson-White syndrome and AV node re-entry tachycardia].
Manz M; Kuhl AJ; Lüderitz B
Z Kardiol; 1985 Sep; 74(9):500-5. PubMed ID: 4060827
[TBL] [Abstract][Full Text] [Related]
4. [Electrophysiologic effect of sotalol in supraventricular tachycardias].
Borggrefe M; Breithardt G
Z Kardiol; 1985 Sep; 74(9):506-11. PubMed ID: 4060828
[TBL] [Abstract][Full Text] [Related]
5. [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
Manz M; Beermann J; Gerckens U; Lüderitz B
Z Kardiol; 1986 Dec; 75(12):757-63. PubMed ID: 3825226
[TBL] [Abstract][Full Text] [Related]
6. [Effect of a new class I anti-arrhythmia agent cibenzoline in patients with therapy refractory, sustained ventricular tachycardias].
Kühlkamp V; Ickrath O; Haasis R; Seipel L
Z Kardiol; 1988 Sep; 77(9):595-9. PubMed ID: 3195178
[TBL] [Abstract][Full Text] [Related]
7. Does sotalol have reverse-use dependence during tachyarrhythmias?
Kovoor P; Byth K; Uther JB; Ross DL
Am J Cardiol; 1996 Jul; 78(2):247-50. PubMed ID: 8712156
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of intravenous sotalol in the treatment of supraventricular tachycardia].
Denis J; Brunel P; Moisan A
Ann Cardiol Angeiol (Paris); 1988; 37(7):387-91. PubMed ID: 3064696
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease.
Kopelman HA; Woosley RL; Lee JT; Roden DM; Echt DS
Am J Cardiol; 1988 May; 61(13):1006-11. PubMed ID: 3284316
[TBL] [Abstract][Full Text] [Related]
10. [Influence of pacing site on myocardial transmural dispersion of repolarization in intact normal and dilated cardiomyopathy dogs].
Bai R; Pu J; Liu N; Lu JG; Zhou Q; Ruan YF; Niu HY; Wang L
Sheng Li Xue Bao; 2003 Dec; 55(6):722-30. PubMed ID: 14695492
[TBL] [Abstract][Full Text] [Related]
11. Heart rate variability in patients suffering from structural heart disease and decreased AV-nodal conduction capacity. Insights into the formation of heart rate variability.
Schwab JO; Eichner G; Schmitt H; Schrickel J; Yang A; Balta O; Lüderitz B; Lewalter T
Z Kardiol; 2004 Mar; 93(3):229-33. PubMed ID: 15024591
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
Kuchar DL; Garan H; Venditti FJ; Finkelstein D; Rottman JN; McComb J; McGovern BA; Ruskin JN
Am J Cardiol; 1989 Jul; 64(1):33-6. PubMed ID: 2741811
[TBL] [Abstract][Full Text] [Related]
13. Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol.
Brachmann J; Senges J; Lengfelder W; Jauernig R; Rizos I; Czygan E; Cobbe SM; Kübler W
Eur Heart J; 1985 Nov; 6 Suppl D():171-4. PubMed ID: 3936715
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiological mechanisms of action of the levorotatory isomer of sotalol in a canine infarct model of inducible ventricular tachycardia: comparison with the beta-1 receptor antagonist bisoprolol.
Aidonidis I; Rizos I; Hilbel T; Kuebler W; Brachmann J
J Mol Cell Cardiol; 1994 Jul; 26(7):841-8. PubMed ID: 7966352
[TBL] [Abstract][Full Text] [Related]
15. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias.
Fujiki A; Tani M; Mizumaki K; Shimono M; Inoue H
J Cardiovasc Pharmacol; 1994 Mar; 23(3):374-8. PubMed ID: 7515979
[TBL] [Abstract][Full Text] [Related]
17. [The anti-arrhythmia effect and hemodynamic effects of Bonnecor in intravenous administration].
Volkmann H; Kühnert H; Dannberg G; Küch N; Büttner A
Z Gesamte Inn Med; 1989 Dec; 44(23):707-11. PubMed ID: 2629366
[TBL] [Abstract][Full Text] [Related]
18. Spatial dispersion of action potential duration restitution kinetics is associated with induction of ventricular tachycardia/fibrillation in humans.
Pak HN; Hong SJ; Hwang GS; Lee HS; Park SW; Ahn JC; Moo Ro Y; Kim YH
J Cardiovasc Electrophysiol; 2004 Dec; 15(12):1357-63. PubMed ID: 15610278
[TBL] [Abstract][Full Text] [Related]
19. [Electrophysiological effects of flecainide on stimulus-inducible ventricular tachycardia].
Breithardt G; Borggrefe M; Yeh HL; Seipel L
Z Kardiol; 1982 Apr; 71(4):278-83. PubMed ID: 7090468
[TBL] [Abstract][Full Text] [Related]
20. [Intravenous sotalol in the acute treatment of supraventricular tachycardias].
Lévy S; Rovini JC; Metge M; Cointe R; Bru P; Nassi C; Gérard R
Arch Mal Coeur Vaiss; 1986 Nov; 79(12):1781-5. PubMed ID: 3105490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
